Testing effectiveness (Phase 2)Enrolling By InvitationNCT06275620
What this trial is testing
A Study Comparing Two Doses of AGTC-501 in Male Participants With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (DAWN)
Who this might be right for
X-Linked Retinitis Pigmentosa
Beacon Therapeutics 24